1. Ibrutinib (Imbruvica®) Medical Review NDA 20552, FDA October 2013.
2. Ibrutinib (Imbruvica®) Pharmacology Review NDA 20552, FDA August 2013.
3. Imbruvica® (ibrutinib) Prescribing Information, Pharmacyclics Inc, Janssen Biotech Inc. January 2015.
4. Imbruvica® (ibrutinib) Assessment Report WC500177777, EMA July 2014.
5. Imbruvica® (ibrutinib) Assessment Report WC500191947, EMA May 2015.